Information " shallow " read
Group of two when come from Germany and France clinical research learned the 43rd annual meeting to go up to report respectively in American clinical tumour recently say, awasiting can lengthen anticarcinogen content significantly of terminal lung cancer and patient of terminal kidney cancer live without progress period.
Group of two when come from Germany and France according to report of Xinhua News Agency clinical research was in the United States recently clinical tumour society reports respectively on the 43rd annual meeting say, awasiting can lengthen anticarcinogen content significantly of terminal lung cancer and patient of terminal kidney cancer live without progress period.
Live without progress period point to the time span that begins to undertake to tumor afterwards sends a gender to grow remedial occurrence to tumor.
Researcher of college of fort of German sea heart says, they are research target with patient of lung cancer of terminal blame cellule, cure is changed in convention in, join medicaments A gas to low. Result discovery, with use convention to change cure photograph to compare only, of the patient changing cure that takes Awasiting live without progress period lengthened 20% to 30% , tumor can rise at most to effective and respondent rate of cure 70% , effective and respondent duration can increase 6.1 months from 4.7 months.
Lung cancer disease has 80% above to belong to blame cellule lung cancer in the exemple. The expert that participates afore-mentioned research says, in terminal blame at present cellule lung cancer treats a field, change cure and put cure to did not obtain the remarkable in that way result in be being treated like other cancer, because this is terminal,patient of blame cellule lung cancer needs more significant curative thing.
France researcher of college of Luxi of · of Ju Sida's husband is investigation object with patient of cancer of terminal kidney cell, be in interferon treatment program of the standard is at present medium, join Awasiting. Result discovery, with use interferon to treat photograph comparing only, after adding Awasiting, of the patient live without progress period can lengthen from 5.4 months to 10.2 months, the tumor effective and respondent rate to cure but from 12.8% rise to 31.4% .
Awasiting is research and development of company of pharmacy of Swiss collect family name fight cancerous new drug, remedial potential all was shown in the process that it is coping with lung cancer of cellule of colonic cancer, rectum cancer, breast cancer, blame and kidney cell cancer. At present this medicine already served as a gleam of to medication permissibly in Europe terminal and colonic cancer, rectum cancer and move sex breast cancer.